AIM ImmunoTech Shares Are Trading Higher After the Company Announced Preliminary Data From Its Phase 1b/2 Study of Ampligen and Imfinzi.
AIM ImmunoTech Shares Are Trading Higher After the Company Announced Preliminary Data From Its Phase 1b/2 Study of Ampligen and Imfinzi.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.